Table 2. Association between rs6812193 and rs6825004 genotypes and Parkinson’s disease.
| Status |
Controls (n=272)
|
PD Cases (n=548)
|
P-value for PD risk | OR for PD (95% CI) a | ||
|---|---|---|---|---|---|---|
| N (%) | GCase enzymatic activity b μmol/l/h (s.d.) | N (%) | GCase enzymatic activity b μmol/l/h (s.d.) | |||
|
rs6812193
| ||||||
| C/C | 115 (42.3%) | 11.97 (3.31) | 273 (49.8%) | 11.82 (3.16) | 0.057 | Reference |
| C/T | 123 (45.2%) | 11.96 (2.90) | 229 (41.8%) | 11.70 (3.09) | 0.52 (0.30–0.89); P=0.018 | |
| T/T | 34 (12.5%) | 12.07 (4.43) | 46 (8.4%) | 11.98 (3.10) | 0.62 (0.36–1.07); P=0.086 | |
| C | 353 (64.8%) | 775 (70.7%) | 0.0175 | 0.71 (0.56–0.90); P=0.004c | ||
| T | 191 (35.2%) | 321 (29.3%) | ||||
|
rs6825004
d
| ||||||
| C/C | 125 (46.1%) | 11.94 (3.35) | 243 (44.4%) | 11.63 (2.88) | 0.562 | Reference |
| C/G | 115 (42.4%) | 11.90 (3.22) | 229 (41.9%) | 11.97 (3.42) | 1.03 (0.74–1.45); P=0.833 | |
| G/G | 31 (11.4%) | 12.42 (3.33) | 75 (13.7%) | 11.76 (3.04) | 0.79 (0.48–1.30); P=0.788 | |
| C | 365 (67.3%) | 715 (65.3%) | 0.438 | 1.17 (0.93–1.47); P=0.182c | ||
| G | 177 (32.7%) | 379 (34.7%) | ||||
Abbreviations: CI, confidence interval; OR, odds ratio; PD, Parkinson's disease.
a
OR calculated in models adjusted for age, gender, LRRK2 and GBA mutation status.
b
There was no difference in GCase activity among the genotypes, either in controls or in PD cases. Values presented here after excluding GBA and LRRK2 p.G2019S carriers.
c
Model included sex, age, rs6812193 genotype, and rs6825004 genotype.
d
rs6825004 was missing on one PD and one control participant.